US2012219523A1PendingUtilityA1

Method of treating tuberculosis with interferons

43
Assignee: CONDOS RANYPriority: May 18, 2007Filed: Dec 20, 2011Published: Aug 30, 2012
Est. expiryMay 18, 2027(~0.8 yrs left)· nominal 20-yr term from priority
Inventors:Rany CondosGerald Smaldone
A61P 31/06A61K 31/65A61K 9/0078A61K 31/00A61K 38/21A61K 31/4409
43
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method of treating tuberculosis comprising administering an aerosolized interferon such as interferon α, interferon β or interferon γ in a therapeutically effective amount is provided herein. Further, a method of reducing the infectivity of tuberculosis or reducing the number of infectious organisms present in the lungs of a patient suffering from tuberculosis comprising administering an aerosolized interferon such as interferon α, interferon β or interferon γ in a therapeutically effective amount is provided herein. Also, pharmaceutical compositions of one or more aerosolized interferon(s) are provided.

Claims

exact text as granted — not AI-modified
1 . A method for treating tuberculosis in a subject comprising administering an aerosolized interferon in a therapeutically effective amount. 
     
     
         2 . The method of  claim 1 , wherein the tuberculosis improves as measured by an indication selected from the group consisting of a decrease in fever, a reduction in sputum production, a reduction in wheezing and a reduction in conversion of sputum cultures. 
     
     
         3 . The method of  claim 1 , wherein the subject suffering from the tuberculosis is unresponsive to treatment with one or more antibiotics. 
     
     
         4 . The method of  claim 1 , wherein the tuberculosis is multiple drug resistant (MDR-TB). 
     
     
         5 . The method of  claim 1 , wherein aerosolized interferon is administered at a dose ranging from about 100 to 750 ug at least three times per week. 
     
     
         6 . The method of  claim 1 , wherein aerosolized interferon is administered as a dose of about 200 μg at least three times per week. 
     
     
         7 . The method of  claim 1 , wherein the amount of aerosolized interferon administered is calculated and optimized. 
     
     
         8 . The method of  claim 1 , wherein said administering results in deposition of interferon in the lungs of patients with tuberculosis. 
     
     
         9 . The method of  claim 1 , wherein said administering results in improvement in pulmonary function tests. 
     
     
         10 . The method of  claim 1  wherein the interferon is interferon α. 
     
     
         11 . The method of  claim 1  wherein the interferon is interferon β. 
     
     
         12 . The method of  claim 1  wherein the interferon is interferon γ. 
     
     
         13 . A method of treating a patient having tuberculosis comprising delivering a therapeutically effective amount of an aerosolized interferon in combination with a therapeutically effective amount of an antibiotic agent. 
     
     
         14 . The method of  claim 13 , wherein the antibiotic agent is selected from the group consisting of isoniazid and rifampin. 
     
     
         15 . The method of  claim 13 , wherein the tuberculosis improves as measured by an indication selected from the group consisting of a decrease in fever, a reduction in sputum production, a reduction in wheezing and a reduction in conversion of sputum cultures. 
     
     
         16 . The method of  claim 13 , wherein the subject suffering from tuberculosis is unresponsive to treatment with one or more antibiotics. 
     
     
         17 . The method of  claim 13 , wherein the tuberculosis is multiple drug resistant (MDR-TB). 
     
     
         18 . The method of  claim 13 , wherein aerosolized interferon is administered at a dose ranging from about 100 to 750 ug at least three times per week. 
     
     
         19 . The method of  claim 13 , wherein aerosolized interferon is administered as a dose of about 200 μg at least three times per week. 
     
     
         20 . The method of  claim 13 , wherein the amount of aerosolized interferon administered is calculated and optimized. 
     
     
         21 . The method of  claim 13 , wherein said administering results in deposition of interferon in the lungs of patients with tuberculosis. 
     
     
         22 . The method of  claim 13 , wherein said administering results in improvement in pulmonary function tests. 
     
     
         23 . The method of  claim 13  wherein the interferon is interferon α. 
     
     
         24 . The method of  claim 13  wherein the interferon is interferon β. 
     
     
         25 . The method of  claim 13  wherein the interferon is interferon γ. 
     
     
         26 . A pharmaceutical composition comprising a therapeutically effective amount of aerosolized interferon for treatment of patients having tuberculosis. 
     
     
         27 . A pharmaceutical composition according to  claim 26  further comprising an antibiotic. 
     
     
         28 . A pharmaceutical composition according to  claim 26 , wherein the antibiotic is selected from the group consisting of isoniazid and rifampin. 
     
     
         29 . A pharmaceutical composition according to  claim 26 , wherein the subject suffering from tuberculosis is unresponsive to treatment with one or more antibiotics. 
     
     
         30 . A pharmaceutical composition according to  claim 26 , wherein the interferon is interferon α. 
     
     
         31 . A pharmaceutical composition according to  claim 26 , wherein the interferon is interferon β. 
     
     
         32 . A pharmaceutical composition according to  claim 26 , wherein the interferon is interferon γ. 
     
     
         33 . A method for reducing the infectivity of tuberculosis in a subject comprising administering an aerosolized interferon-γ in a therapeutically effective amount. 
     
     
         34 . The method of  claim 33 , wherein the tuberculosis improves as measured by an indication selected from the group consisting of a decrease in fever, a reduction in sputum production, a reduction in wheezing and a reduction in conversion of sputum cultures. 
     
     
         35 . The method of  claim 33 , wherein the subject suffering from the tuberculosis is unresponsive to treatment with one or more antibiotics. 
     
     
         36 . The method of  claim 33 , wherein the tuberculosis is multiple drug resistant (MDR-TB). 
     
     
         37 . The method of  claim 33 , wherein aerosolized interferon is administered at a dose ranging from about 100 to 750 ug at least three times per week. 
     
     
         38 . The method of  claim 33 , wherein aerosolized interferon is administered as a dose of about 200 μg at least three times per week.

Join the waitlist — get patent alerts

Track US2012219523A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.